Theralase Updates Cancer Therapy Breakthrough
09 Octobre 2013 - 1:00PM
Access Wire
Toronto, ON, (Accesswire - October 9,
2013) - On
March 28, 2012, Theralase Technologies Inc. (TSXV: TLT) first
announced that its anti-cancer technology was found to completely
destroy highly aggressive, subcutaneous (under the skin) colon
cancer tumours in a mouse model. At that point in time, 4 weeks
post treatment, the mice continued to be cancer free.
Theralase is pleased to announce that the mice have
remained cancer free for a remarkable 20 months and counting after
receiving only 1 Theralase cancer treatment.
"All animals which showed an initial response
have remained cancer free for the entire time, healed without any
scarring and have developed normally after only a single PDC
treatment. This is an extremely good indication of the efficacy of
the Theralase technology and not often observed at this early stage
in new drug development", stated Dr. Lothar Lilge, a
Senior Scientist at the Ontario Cancer Institute, Princess Margaret
Cancer Centre, University Health Network and Professor of Medical
Biophysics at the University of Toronto, who was in charge of the
animal experiments.
"This therapy has worked amazingly well in
these animal models and we were all extremely surprised and
delighted that the treatment conferred such a strong anti-cancer
effect and overall survival benefit to the treated animals. We are
in communication with Princess Margaret Cancer Centre's oncologists
to determine the parameters required to start the preparation of a
human clinical trial as soon as possible to see if this
groundbreaking work can be successfully translated to human cancer
patients, possibly even as a first line treatment of bladder
cancer" stated Dr. Arkady Mandel, Chief Scientific Officer of
Theralase Inc."
Dr. Mandel went on to say that, "In cancer treatment,
destroying the tumour is half the battle, while the other more
important half is preventing the cancer from recurring, while
preserving normal organ function. These findings are vitally
important because they clearly demonstrate that our leading drug
candidate, in combination with a specific dose of light, can
destroy the cancer in the first instance, but more importantly
prevent the cancer from recurring for a significant time
period."
Roger Dumoulin-White,
President and CEO of Theralase Inc. stated, "The achievement of
this important milestone signifies that Theralase's leading cancer
therapy is very effective in the destruction of cancer in a live
animal model, but more importantly can prevent the
cancer from recurring for years after treatment. The key to this
research is that our lead cancer is bladder cancer, a cancer which
has historically demonstrated a recurrence rate of
80%. If the Theralase cancer therapy is able to
reproduce these results in humans, and there is no reason to
believe it will not, then I believe we have an extremely important
discovery in the fight against cancer. As a final note on the potency of these new
class of drugs, in our
cell based experiments, the lead Theralase PDC was found to be
668,000 times more effective than ALA and 198 times more effective
than PHOTOFRIN(R), two currently approved FDA photoactive
drugs."
About Theralase
Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs,
develops, manufactures and markets patented, superpulsed laser
technology utilized in both healing and destroying tissue. The
healing technology is safe and effective in the treatment of pain,
inflammation and the acceleration of tissue healing for a wide
range of nerve, muscle and joint conditions. The destructive
technology enlists patented Photo Dynamic Compounds (PDCs), which
when light activated, have the ability to specifically target and
effectively destroy cancer, bacteria and viruses.
For further information please visit www.theralase.com,
regulatory filings may be viewed by visiting www.sedar.com.
This press release contains
forward-looking statements which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & Chief Executive Officer
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024